Published in Clin Cancer Res on April 29, 2013
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget (2014) 0.96
Targeting Notch to overcome radiation resistance. Oncotarget (2016) 0.82
Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition. J Neuropathol Exp Neurol (2015) 0.82
The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett (2016) 0.81
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. Sci Rep (2016) 0.80
Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget (2016) 0.78
Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. Acta Neuropathol Commun (2014) 0.78
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget (2016) 0.78
Notch signaling activation in pediatric low-grade astrocytoma. J Neuropathol Exp Neurol (2015) 0.76
Notch1 regulates the JNK signaling pathway and increases apoptosis in hepatocellular carcinoma. Oncotarget (2017) 0.75
An immunocompetent mouse model of human glioblastoma. Oncotarget (2017) 0.75
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature (2005) 11.49
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27
Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006) 3.81
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 3.42
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Heterogeneity maintenance in glioblastoma: a social network. Cancer Res (2011) 2.66
Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res (2007) 2.54
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood (2009) 2.29
Current concepts and management of glioblastoma. Ann Neurol (2011) 2.23
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol (2007) 2.02
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol (2010) 1.86
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg (2007) 1.77
Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 1.73
Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells (2010) 1.72
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci (2011) 1.66
Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res (2011) 1.58
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res (2010) 1.58
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res (2009) 1.54
Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol (2012) 1.52
Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell (2011) 1.49
HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ (2011) 1.40
The functional role of Notch signaling in human gliomas. Neuro Oncol (2009) 1.39
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer (2010) 1.33
Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med (2010) 1.28
Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene (2011) 1.25
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer (2011) 1.23
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res (2010) 1.23
DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells (2009) 1.20
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res (2010) 1.19
Notch, neural stem cells, and brain tumors. Cold Spring Harb Symp Quant Biol (2008) 1.19
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med (2012) 1.14
Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. Cancer Sci (2011) 1.13
The neurobiology of neurooncology. Ann Neurol (2006) 1.09
Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer (2011) 1.07
Notch signaling in glioblastoma: a developmental drug target? BMC Med (2010) 1.04
siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol Biol Rep (2011) 0.98
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res (2009) 0.97
Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett (2009) 0.95
Notch signaling in cancer stem cells. Adv Exp Med Biol (2012) 0.95
γ-secretase inhibitor-I enhances radiosensitivity of glioblastoma cell lines by depleting CD133+ tumor cells. Arch Med Res (2010) 0.92
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer (2011) 0.91
Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion. PLoS One (2011) 0.89
Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor. Mol Cancer (2011) 0.89
Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci (2009) 0.86
Malignant gliomas: new translational therapies. Mt Sinai J Med (2010) 0.85
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006) 3.81
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 3.42
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 2.90
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
The neurobiology of autism. Brain Pathol (2007) 2.63
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell (2002) 2.37
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci (2007) 2.31
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev (2005) 2.14
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol (2010) 1.86
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res (2008) 1.84
Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol (2006) 1.83
A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther (2011) 1.76
Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res (2005) 1.75
c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A (2011) 1.75
Medulloblastoma stem cells. J Clin Oncol (2008) 1.71
Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res (2009) 1.66
c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res (2006) 1.66
A mouse model of blast injury to brain: initial pathological, neuropathological, and behavioral characterization. J Neuropathol Exp Neurol (2011) 1.62
BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res (2011) 1.61
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res (2010) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Unfolded protein response in fuchs endothelial corneal dystrophy: a unifying pathogenic pathway? Am J Ophthalmol (2010) 1.49
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev (2008) 1.42
Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res (2005) 1.40
A clinicopathologic series of primary graft failure after Descemet's stripping and automated endothelial keratoplasty. Ophthalmology (2008) 1.40
Iris cross-sectional area decreases with pupil dilation and its dynamic behavior is a risk factor in angle closure. J Glaucoma (2009) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol (2012) 1.33
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget (2013) 1.28
Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett (2012) 1.26
Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci U S A (2010) 1.25
Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. Am J Surg Pathol (2010) 1.23
Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One (2012) 1.23
Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol (2009) 1.23
Hedgehog signaling promotes medulloblastoma survival via Bc/II. Am J Pathol (2007) 1.22
DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells (2009) 1.20
Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J Biol Chem (2007) 1.19
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer (2014) 1.14
Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14
Epithelial downgrowth following Descemet's-stripping automated endothelial keratoplasty. Arch Ophthalmol (2008) 1.14
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol (2012) 1.14
Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4. Proc Natl Acad Sci U S A (2013) 1.12
hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol (2003) 1.11
Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest (2007) 1.10
Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol (2011) 1.10
Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget (2012) 1.09
Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells (2011) 1.09
Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol (2012) 1.09
RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer (2009) 1.08
Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic Biol Med (2011) 1.08
LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget (2013) 1.05
Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol (2012) 1.04
Identification of astrocytoma associated genes including cell surface markers. BMC Cancer (2004) 1.04
DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One (2012) 1.02
Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res (2012) 1.01
Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res (2011) 1.01
Transforming growth factor-β signaling pathway activation in Keratoconus. Am J Ophthalmol (2011) 1.00
Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol (2005) 1.00
Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol (2008) 1.00
Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol (2013) 0.99
Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 and their epigenetic status in medulloblastoma and astrocytoma. BMC Cancer (2010) 0.99
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res (2012) 0.98
Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res (2007) 0.98
NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol (2010) 0.97
Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol (2007) 0.97
Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro Oncol (2008) 0.96
beta2-adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. J Child Neurol (2005) 0.95
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro Oncol (2013) 0.95